Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Mezagitamab

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP) .

Product Specifications

CAS Number

2227490-52-8

Stability

≥ 2 years

Purity

>98% (HPLC)

Molecular Formula

——

Notes

Research use only, not for human use.

Receptor

CD38

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

1- (Pyridin-3-yl) cyclopropan-1-amine bis (4-nitrobenzoate)
OR1032617-01 100 mg

1- (Pyridin-3-yl) cyclopropan-1-amine bis (4-nitrobenzoate)

Sign In for Pricing
View Details
1- (Pyridin-3-yl) cyclopropan-1-amine bis (4-nitrobenzoate)
OR1032617-02 250 mg

1- (Pyridin-3-yl) cyclopropan-1-amine bis (4-nitrobenzoate)

Sign In for Pricing
View Details
1- (Pyridin-3-yl) cyclopropan-1-amine bis (4-nitrobenzoate)
OR1032617-03 1 g

1- (Pyridin-3-yl) cyclopropan-1-amine bis (4-nitrobenzoate)

Sign In for Pricing
View Details
CAV3, NT (Caveolin-3, M-caveolin) (FITC) discontinued
C2097-98B-FITC 200 µL

CAV3, NT (Caveolin-3, M-caveolin) (FITC) discontinued

Sign In for Pricing
View Details
Recombinant Human EOLA2 Protein
E30P9830 20 µg

Recombinant Human EOLA2 Protein

Sign In for Pricing
View Details
CPT2 (Carnitine O-palmitoyltransferase 2, Mitochondrial, Carnitine Palmitoyltransferase II, CPT II, CPT1) (MaxLight 750) discontinued
125298-ML750 100 µL

CPT2 (Carnitine O-palmitoyltransferase 2, Mitochondrial, Carnitine Palmitoyltransferase II, CPT II, CPT1) (MaxLight 750) discontinued

Sign In for Pricing
View Details